尽管最近利润下降,但Aurobindo Pharma仍从新的中国设施向欧洲市场供应。 Aurobindo Pharma to supply European market from new China facility, despite recent profit drop.

印度药品制造商Aurobindo Pharma计划从4月开始从中国新设施向欧洲供应产品。 Aurobindo Pharma, an Indian drug manufacturer, plans to supply products from its new China facility to Europe starting in April. 该公司于2024年11月在该设施开始运作,并获得了欧洲管制批准。 The company began operations at the facility in November 2024 and has received European regulatory approvals. Aurobindo预计未来几年市场业绩强劲,特别是其生物部门,预计到2028-30年将有七种产品商业化。 Aurobindo expects strong market performance over the next few years, especially in its biologics segment, with seven products projected to be commercialized by 2028-30. 尽管净利润下降了10%,但该公司报告说,到2024年12月31日为止的季度收入有所增加。 Despite a 10% drop in net profit, the company reported increased revenue for the quarter ending December 31, 2024.